The use of enoxaparin compared with unfractionated heparin for short-term antithrombotic therapy in atrial fibrillation patients undergoing transoesophageal echocardiography-guided cardioversion: Assessment of Cardioversion Using Transoesophageal Echocardiography (ACUTE) II randomized multicentre study

European Heart Journal

Volumn 27, Issue 23, 2006, Pages 2858-2865

  Klein, Allan L ^e   Jasper, Susan E ^f   Katz, William E ^a   Malouf, Joseph F ^b   Pape, Linda A ^c   Stoddard, Marcus F ^d   Apperson Hansen, Carolyn ^f   Lieber, Elizabeth A ^f  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

^c UMASS MEMORIAL MEDICAL CENTER   (United States)

^d University of Louisville School of Medicine   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f NONE

Author keywords

Atrial fibrillation; Cardioversion; Enoxaparin; Transoesophageal echocardiography

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; SODIUM CHANNEL BLOCKING AGENT; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG SAFETY; ECCHYMOSIS; EMBOLISM; FEASIBILITY STUDY; FEMALE; HEART ATRIUM FIBRILLATION; HEMATOMA; HUMAN; LENGTH OF STAY; MALE; MULTICENTER STUDY; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SINUS RHYTHM; THROMBOSIS; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; VAGINA BLEEDING;

ATRIAL FIBRILLATION; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; ELECTRIC COUNTERSHOCK; ENOXAPARIN; FEASIBILITY STUDIES; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 33845309640     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehl353     Document Type: Article

References (21)

1. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, LeHeuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation- Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006;48:854-906.
2. Lown B. Electrical reversion of cardiac arrhythmias. Br Heart J 1967;29:469-489.
3. Manning WJ, Silverman DI, Keighley CS, Oettgen P, Douglas PS. Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4. 5-year study. J Am Coll Cardiol 1995;25:1354-1361.
4. Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW, Davidoff R, Erbel R, Halperin JL, Orsinelli DA, Porter TR, Stoddard MF; Assessment of Cardioversion Using Transesophageal Echocardiography Investigators. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001;344:1411-1420.
5. Murray RD, Deitcher SR, Shah A, Jasper SE, Bashir M, Grimm RA, Klein AL. Potential clinical efficacy and cost benefit of a transesophageal echocardiography-guided low-molecular-weight heparin (enoxaparin) approach to antithrombotic therapy in patients undergoing immediate cardioversion from atrial fibrillation. J Am Soc Echocardiogr 2001;14:200-208.
6. Klein AL, Murray RD, Grimm RA. Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation. J Am Coll Cardiol 2001;37:691-704.
7. Turpie AG, Mason JA. Review of enoxaparin and its clinical applications in venous and arterial thromboembolism. Expert Opin Pharmacother 2002;3:575-598.
8. Murray RD, Shah A, Jasper SE, Goodman A, Deitcher SR, Katz WE, Malouf JF, Stoddard MF, Grimm RA, Klein AL. Transesophageal echocardiography guided enoxaparin antithrombotic strategy for cardioversion of atrial fibrillation: the ACUTE II pilot study. Am Heart J 2000;139:1-7.
9. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:188S-203S.
10. Steering and Publications Committees of the ACUTE Study. Design of a clinical trial for the assessment of cardioversion using transesophageal echocardiography (The ACUTE Multicenter Study). Am J Cardiol 1998;81:877-883.
11. Miller JM, Zipes DP. Therapy for cardiac arrhythmias. In: Zipes DP, Libby P, Bonow RO, Braunwald E, eds., Braunwald's Heart Disease. 7th ed. Philadelphia, PA: Elsevier Saunders; 2005. p713-766.
12. Zhao L, Lewis C, Jasper SE, Klein AL, Weintraub WS. Economic analysis of LMWH strategy compared with unfractionated heparin strategy for cardioversion of atrial fibrillation using transesophageal echocardiography: results from the ACUTE II study. J Am Coll Cardiol 2006;47(Suppl. B): 1B[2901-2962].
13. Grimm RA, Leung DY, Black IW, Stewart WJ, Thomas JD, Klein AL. Left atrial appendage 'stunning' after spontaneous conversion of atrial fibrillation demonstrated by transesophageal Doppler echocardiography. Am Heart J 1995;130:174-176.
14. Manduteanu I, Voinea M, Capraru M, Dragomir E, Simionescu M. A novel attribute of enoxaparin: inhibition of monocyte adhesion to endothelial cells by a mechanism involving cell adhesion molecules. Pharmacology 2002;65:32-37.
15. Thambidorai SK, Parakh K, Martin DO, Shah TK, Wazni O, Jasper SE, Van Wagoner DR, Chung MK, Murray RD, Klein AL. Relation of C-reactive protein correlates with risk of thromboembolism in patients with atrial fibrillation. Am J Cardiol 2004;94:805-807.
16. Malouf JF, Kanagala R, Al Atawi FO, Rosales AG, Davison DE, Murali NS, Tsang TS, Chandrasekaran K, Ammash NM, Friedman PA, Somers VK. High sensitivity C-reactive protein: a novel predictor for recurrence of atrial fibrillation after successful cardioversion. J Am Coll Cardiol 2005;46:1284-1287.
17. Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, Geller C, Mugge A, Sehnert W, Schmidt-Lucke C, Schmidt-Lucke JA, ACE (Anticoagulation in Cardioversion using Enoxaparin) Study Group. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation 2004; 109:997-1003.
18. de Luca I, Sorino M, De Luca L, Colonna P, Del Salvatore B, Corliano L. Pre- and post-cardioversion transesophageal echocardiography for brief anticoagulation therapy with enoxaparin in atrial fibrillation patients: a prospective study with a 1-year follow-up. Int J Cardiol 2005;102:447-454.
19. Halperin JL. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation. J Am Coll Cardiol 2005;45:1-9.
20. Bauer KA. New anticoagulants: anti IIa vs. anti Xa-is one better? J Thromb Thrombolysis 2006;21:67-72.
21. Wu LA, Chandrasekaran K, Friedman PA, Ammash NM, Ramakrishna G, Hart CY, Moon BS, Herges RM, Rosales AG, Malouf JF. Safety of expedited anticoagulation in patients undergoing transesophageal echocardiographic-guided cardioversion. Am J Med 2006;119:142-146.